Is ANI Pharmaceuticals, Inc. (ANIP) a Buy, Sell, or Hold?
NASDAQ : ANIP
ANI Pharmaceuticals, Inc.
$82.69 USD
$1.87 (2.31%)
- Volume
- 69.18K
- Average Volume
- 345.21K
- Market Capitalization
- $1.88B
- P/E Ratio
- 20.12
- Dividend Yield
- 0.00%
- Price Target
- $94.00
- Year High
- $99.50
- Year Low
- $62.61
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.01
- Current Ratio
- $3.12
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Nikhil Lalwani |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Current Symbol | ANIP |
| CUSIP | 00182C103 |
| CIK | 0001023024 |
| Web | https://www.anipharmaceuticals.com |
| Phone | 218 634 3500 |
| Currency | USD |
| Employees | 970 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.58 |
| Payout Ratio | 0.01 |
| Current Ratio | 3.12 |
| Quick Ratio | 2.52 |
| Cash Ratio | 1.30 |
Sales & Book Value
| Annual Sales | $883.37M |
| Price / Sales | 2.04 |
| Cash Flow | 7.67 |
| Price / Cash Flow | 11.72 |
| Price / Book | 3.08 |
Price Target and Rating
| Average Stock Price Forecast | $94.00 |
| High Stock Price Forecast | $124.00 |
| Low Stock Price Forecast | $83.00 |
| Forecast Upside/Downside | -12.03% |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 10 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $3.32 |
| Trailing P/E Ratio | 20.12 |
| PEG Ratio | 0.01 |
| P/E Growth | 0.01 |
| Net Income | $78.34M |
| Net Margin | 9.71% |
| Pretax Margin | 12.56% |
| Return on Equity | 17.32% |
| Return on Assets | 6.31% |
Financials Score
| AltmanZ Score | 2.71 |
| Piotroski Score | 7.00 |
| Working Capital | 507.57M |
| Total Assets | 1.42B |
| Ebit | 145.26M |
| Market Cap | 1.84B |
| Total Liabilities | 859.67M |
Poll Results
About ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota. ...
ANI Pharmaceuticals reports Phase 4 data for uveitis eye implant
2026-07-13 12:55:34
ANI Pharmaceuticals Inc (NASDAQ:ANIP) reported positive topline data from a Phase 4 trial of its fluocinolone acetonide intravitreal implant in chronic non-infectious uveitis, drawing on results from its open-label SYNCHRONICITY study, the company said. ANI Pharmaceuticals said the SYNCHRONICITY trial was a Phase 4, open-label, single-arm study of the fluocinolone acetonide intravitreal implant in patients with chronic non-infectious uveitis affecting the posterior segment of the eye, a condition the company abbreviated as chronic NIU-PS.
ANI Pharmaceuticals reports Phase 4 data for uveitis eye implant
2026-07-13 08:46:00
ANI Pharmaceuticals Inc (NASDAQ:ANIP) reported positive topline data from a Phase 4 trial of its fluocinolone acetonide intravitreal implant in chronic...
2026-07-13 06:50:00
PRINCETON, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced positive topline data from its Phase 4, open-label, single-arm SYNCHRONICITY clinical trial of Fluocinolone Acetonide Intravitreal Implant in patients with chronic non-infectious uveitis affecting the posterior segment of the eye (chronic NIU-PS).
ANI Pharmaceuticals' CFO Sold $285,000 in Stock After a 32% Run
2026-07-12 20:20:17
The executive disposed of 3,313 shares on July 2, 2026, for a total transaction value of about $285,000. The transaction represented 2% of the insider's total direct equity holdings in the company.
ANI Pharmaceuticals CFO Sells $240,000 in Stock After a 42% Cortrophin Surge
2026-07-09 17:36:46
An ANI Pharmaceuticals executive reported selling 2,850 shares directly for about $240,000 on June 29, 2026. The sale represented 1.58% of Carey's direct holdings, reducing his direct stake to 177,543 shares post-transaction.
Here's Why ANI Pharmaceuticals (ANIP) is a Strong Growth Stock
2026-07-02 10:46:08
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
ANI Pharmaceuticals: Rare Disease Growth At A Generics Multiple
2026-06-26 10:26:34
ANI Pharmaceuticals is rated a speculative buy, with the investment thesis centered on Cortrophin Gel's rare disease revenue growth and transformation. Management guides to $540M-$575M Cortrophin revenue in 2026, making rare disease close to 60% of total revenue and supporting a re-rating. A $108 fair value is based on 9x 2026 adjusted EBITDA, offering ~30% upside if Cortrophin growth and gout expansion materialize as guided.
Here's Why ANI Pharmaceuticals (ANIP) is a Strong Growth Stock
2026-06-16 10:46:03
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Frequently Asked Questions
-
What is the current ANI Pharmaceuticals, Inc. (ANIP) stock price?
-
ANI Pharmaceuticals, Inc.(NASDAQ:ANIP) stock price is $82.69 in the last trading session. During the trading session, ANIP stock reached the peak price of $99.5 while $62.61 was the lowest point it dropped to. The percentage change in ANIP stock occurred in the recent session was 2.31% while the dollar amount for the price change in ANIP stock was $1.87.
-
ANIP's industry and sector of operation?
-
The NASDAQ listed ANIP is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.
-
Who are the executives of ANIP?
-
Chad Gassert | Senior Vice President of Corporate Development & Strategy
Christopher K. Mutz | Senior Vice President & Head of Rare Disease
Nikhil Lalwani | President, Chief Executive Officer & Director
Ori Gutwerg | Senior Vice President of Generics
Stephen Carey | Senior Vice President of Finance & Chief Financial Officer -
How many employees does ANIP have?
-
Number of ANIP employees currently stands at 970. ANIP operates from 210 Main Street West, Baudette, MN 56623, US.
-
Link for ANIP official website?
-
Official Website of ANIP is: https://www.anipharmaceuticals.com
-
How do I contact ANIP?
-
ANIP could be contacted at phone #218 634 3500 and can also be accessed through its website. ANIP operates from 210 Main Street West, Baudette, MN 56623, US.
-
How many shares of ANIP are traded daily?
-
The average number of ANIP shares traded daily for last 3 months was 345.21K.
-
What is the market cap of ANIP currently?
-
The market value of ANIP currently stands at $1.88B with its latest stock price at $82.69